Global Stem Cell Therapy Market Overview:
According to SPER Market Research, the Stem Cell Therapy Market estimated to reach USD 700.19 million by 2030 with a CAGR of 15.8%. The fuels for the escalation of the Stem Cell Therapy Market are; increasing stem cell research and GMP-certified facilities to manufacture stem cells, rising demand for induced pluripotent stem cells.
Impact of COVID-19 on the Stem Cell Therapy Market
COVID-19 outbreak has a positive impact on the Stem Cell Therapy Market.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2019-2030 |
| Base year considered | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | By Type, By Cell Source, By Therapeutic Application, By Region
|
| Geographies covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
| Companies Covered | AlloSource, Anterogen, BioRestorative Therapies, BrainStorm Cell Therapeutics, Cellular Biomedicine Group, CORESTEM, Holostem Terapie Avanzate S.r.l, Hope Biosciences, JCR Pharmaceuticals, Kangstem Biotech, MEDIPOST, Mesoblast, NuVasive, Orthofix, Personalized Stem Cells, PHARMICELL, Pluristem Therapeutics, Regrow Biosciences, RTI Surgical, Smith & Nephew Stempeutics Research, Under Pipeline Athersys, Takeda Pharmaceutical Company, ViaCyte
|
Driver: funding for stem cell research
Availability of funding for stem cell research, increasing GMP-certification approvals for cell therapy production facilities, increasing clinical trials for stem cell based-therapies; are the key driver for the expansion of this market.
Restraints:
Ethical concerns related to embryonic stem cells, costly cell-based research; are the restraint to the market growth.
Opportunity:
Growing demand for cell & gene therapies, the emergence of induced pluripotent stem cells alternative to embryonic stem cells; provide huge opportunities for the players in the market.
Global Stem Cell Therapy Market Segmentation:
By Type: Based on the Type, Global Stem Cell Therapy Market is segmented as; Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy.
By Cell Source: Based on the Cell Source, Global Stem Cell Therapy Market is segmented as; Adipose tissue-derived MSCs (mesenchymal stem cells), Bone marrow-derived MSCs, Placental/umbilical cord-derived MSCs, and Other Cell Sources.
By Therapeutic Application: Based on the Therapeutic Application, Global Stem Cell Therapy Market is segmented as; Cardiovascular Diseases, Inflammatory & Autoimmune Diseases, Musculoskeletal Disorders, Neurological Disorders, Surgeries, Wounds & Injuries, Other Therapeutic Applications.
By Region: North America owns the biggest share of this Stem Cell Therapy Market; this is due to growing public-private partnership funding, research grants to develop safe & effective stem cell therapy products, and increasing figure of clinical trials.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Stem Cell Therapy Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Stem Cell Therapy Market, By Type, 2019-2030 (USD Million)
6.1. Allogeneic Stem Cell Therapy
6.2. Autologous Stem Cell Therapy
7. Global Stem Cell Therapy Market, By Cell Source, 2019-2030 (USD Million)
7.1. Adipose tissue-derived MSCs (mesenchymal stem cells),
7.2. Bone marrow-derived MSCs,
7.3. Placental/umbilical cord-derived MSCs, and
7.4. Other Cell Sources
8. Global Stem Cell Therapy Market, By Therapeutic Application, 2019-2030 (USD Million)
8.1. Cardiovascular Diseases
8.2. Inflammatory & Autoimmune Diseases
8.3. Musculoskeletal Disorders
8.4. Neurological Disorders,
8.5. Other Therapeutic Applications
8.6. Surgeries,
8.7. Wounds & Injuries
9. Global Stem Cell Therapy Market, By Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. Company Profiles
10.1. AlloSource
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Anterogen
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. BioRestorative Therapies
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. BrainStorm Cell Therapeutics
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Cellular Biomedicine Group
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. CORESTEM
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Holostem Terapie Avanzate S.r.l
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Hope Biosciences
10.7.5. Company details
10.7.6. Financial outlook
10.7.7. Product summary
10.7.8. Recent developments
10.9. JCR Pharmaceuticals
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.10. Kangstem Biotech
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. MEDIPOST
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. Mesoblast
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. NuVasive
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. Orthofix
10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. Personalized Stem Cells
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. PHARMICELL
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments
10.17. Pluristem Therapeutics
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments
10.18. Regrow Biosciences
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments
10.19. RTI Surgical
10.18.5. Company details
10.18.6. Financial outlook
10.18.7. Product summary
10.18.8. Recent developments
10.20. Smith & Nephew
10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments
10.21. Stempeutics Research
10.21.1. Company details
10.21.2. Financial outlook
10.21.3. Product summary
10.21.4. Recent developments
10.22. Under Pipeline Athersys
10.22.1. Company details
10.22.2. Financial outlook
10.22.3. Product summary
10.22.4. Recent developments
10.23. Takeda Pharmaceutical Company
10.23.1. Company details
10.23.2. Financial outlook
10.23.3. Product summary
10.23.4. Recent developments
10.24. ViaCyte
10.24.1. Company details
10.24.2. Financial outlook
10.24.3. Product summary
10.24.4. Recent developments
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
